Novartis AG stock (CH0012005267): oncology focus, new drug readout and solid 2025 guidance in view

Novartis AG remains in focus after recent clinical trial updates and reiterated 2025 guidance, while the share continues to trend higher on the NYSE. What drives the pharma group’s earnings power – and what matters for US investors now.

Novartis AG has stayed in the headlines in recent weeks as the Swiss pharma group reported new clinical data for key pipeline drugs and reiterated its medium-term guidance at investor events, while the stock continued to trade near multi?year highs on the NYSE. Recent updates included positive Phase III results in immunology and oncology as well as commentary on cost discipline and capital allocation, according to Novartis investor information as of 04/30/2025 and coverage by Reuters as of 03/15/2025.

As of: 22.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Novartis
• Sector/industry: Pharmaceuticals, healthcare
• Headquarters/country: Basel, Switzerland
• Core markets: United States, Europe, international markets
• Key revenue drivers: Innovative prescription medicines in oncology, cardiovascular, immunology and neuroscience
• Home exchange/listing venue: SIX Swiss Exchange, American Depositary Shares on NYSE (ticker: NVS)
• Trading currency: CHF in Zurich, USD on NYSE

Novartis AG: core business model

Novartis AG is one of the world’s largest research?driven pharmaceutical groups, with a strategic focus on patented prescription medicines rather than generics. The company generates the vast majority of its revenue from so?called innovative medicines that address chronic and severe diseases, according to its annual report for 2024 published on 01/31/2025. In recent years, it has sharpened this focus by spinning off its generics arm, Sandoz, and divesting non?core assets.

The group organizes its activities primarily around therapeutic areas with high medical need and commercial potential, including oncology, cardiovascular and metabolic disorders, immunology, neuroscience and ophthalmology. Management highlights that blockbuster products and recently launched drugs are the main contributors to profit growth, while mature brands tend to face increasing competition and price pressure, as detailed in the 2024 annual filing released on 01/31/2025. This portfolio mix drives a continuous need for R&D investment and disciplined life?cycle management.

Novartis operates a global R&D network with major sites in Switzerland and the United States, and it spends a double?digit percentage of its annual sales on research and development. In the 2024 financial year, the company reported multi?billion?dollar R&D expenses and emphasized late?stage clinical programs as a key value driver, according to its 2024 annual report published on 01/31/2025. This pipeline?driven model means that positive or negative trial readouts can have a significant effect on investor sentiment and future earnings expectations.

Main revenue and product drivers for Novartis AG

The revenue base of Novartis is concentrated in a number of high?profile medicines that enjoy patent protection and strong demand in their respective indications. These include drugs in oncology and cardiology, among others, which together represent a substantial portion of group sales, according to the 2024 annual report released on 01/31/2025. For investors, the performance and durability of these franchises are central to assessing medium?term cash flows.

Geographically, the United States is the single most important market for Novartis in terms of revenue, with a significant share of sales generated from US patients and healthcare systems. Europe and other international markets provide additional diversification but generally show slower pricing growth due to tighter reimbursement regimes, as outlined in the company’s 2024 annual filing dated 01/31/2025. This exposure means changes in US regulation, reimbursement policy or competitive dynamics can have a direct impact on group profitability.

In addition to established blockbusters, the group is counting on a series of late?stage pipeline candidates and recent launches to offset patent expiries. Management has highlighted upcoming milestones in oncology and immunology, where recent trial successes support the case for future revenue streams, according to company presentations referenced by Reuters as of 03/15/2025. For investors, the balance between patent cliffs and new product growth remains a central theme.

Why Novartis AG matters for US investors

For US investors, Novartis AG is accessible via American Depositary Shares listed on the NYSE under the ticker NVS, which trade in US dollars and can be held like domestic stocks. The US market is not only a listing venue but also a key driver of the company’s sales, meaning trends in American drug pricing, insurance coverage and regulatory scrutiny have a direct influence on earnings, as noted in the 2024 annual report released on 01/31/2025.

Novartis is considered part of the global large?cap pharmaceutical universe that many US?based investors use for diversification and defensive exposure within healthcare. Earnings profiles in this peer group can be less cyclical than in many other sectors, although individual drug?level risks and patent cycles can cause volatility around news events, according to sector commentary from Reuters as of 02/20/2025. The stock’s combination of dividend payments and potential for pipeline?driven growth is often cited in institutional discussions.

Because Novartis reports in Swiss francs but trades actively in US dollars through its NYSE listing, currency movements can affect reported figures for US investors. In periods of dollar strength, reported ADR results may differ from underlying local?currency trends, which is highlighted in management’s discussion of foreign exchange effects in the 2024 annual report published on 01/31/2025. This adds an additional layer of complexity when comparing Novartis to purely US?based peers.

Conclusion

Novartis AG remains a globally important pharmaceutical company with a strong presence in the United States and a business model built around innovative, patent?protected medicines. Recent clinical updates and reiterated guidance have kept the stock in focus, while the share price on the NYSE reflects expectations for continued pipeline execution and cost discipline, according to coverage by Reuters as of 03/15/2025. For US investors, the combination of large?cap scale, exposure to key therapeutic areas and currency considerations offers both opportunities and risks that warrant close monitoring around earnings and major pipeline milestones.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.